Foamix Pharmaceuticals Ltd. June 15th Short Interest Update

Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) has witnessed a drop of 1.1% or 26,288 shares in its short figure. The short interest diminution took it from 2,323,625 on May 31,2016 to 2,297,337 on June 15,2016. In terms of floated shares, the short interest was calculated to be 9.6%. The days to cover are 15 given that the daily volume averaged 151,974 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.

Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX): The stock opened at $6.00 on Friday but the bulls could not build on the opening and the stock topped out at $6.11 for the day. The stock traded down to $5.75 during the day, due to lack of any buying support eventually closed down at $6.07 with a loss of -1.14% for the day. The stock had closed at $6.14 on the previous day. The total traded volume was 2,398,227 shares.

The company shares have dropped -42.25% from its 1 Year high price. On Aug 3, 2015, the shares registered one year high at $12.20 and the one year low was seen on Mar 17, 2016. The 50-Day Moving Average price is $6.56 and the 200 Day Moving Average price is recorded at $6.74.

Stocks of Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) rallied by 1.68% during the past week but lost 15.11% on a 4-week basis. The company has outperformed the S&P 500 by 3.36% in the past week but underperformed the index by 12.54% in the last 4 weeks.

Foamix Pharmaceuticals Ltd. is a clinical-stage specialty pharmaceutical company focused on developing and commercializing its minocycline foam for the treatment of acne, impetigo and other skin conditions. The Companys product candidates include, FMX101 for moderate-to-severe acne, is a topical foam formulation of the antibiotic minocycline; FMX102 for impetigo, FMX103 for rosacea and FDX104 for chemotherapy-induced rash. The Company has conducted only one Phase II clinical trial of each of FMX101 and FMX102 which met the respective primary efficacy and secondary endpoints. The Company developed FMX101, FMX102, FMX103 and FDX104 using its technology, which includes its foam-based platforms. This technology enables it to formulate and stabilize a variety of drugs and deliver them directly to target site. The Company has entered into development and license agreements relating to its technology with Bayer HealthCare AG (Intendis), Merz Pharmaceuticals, LLC and Actavis plc.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.